Customers often expand the number of projects with us as they recognize ABL's breadth of technical capabilities. • One of our large biopharmaceutical customers recognized the value of ABL as a strategic partner in providing access to centralized data that the customer can trust and rely on. • They view the consistency of instrumentation and their relationships with ABL as difference makers. • Find out more about us: https://ablinc.com/
Customers often expand the number of projects with us as they recognize ABL's breadth of technical capabilities. • One growing biotech company has extended their indications from infectious disease in HPV and HIV to oncology indications, as well as from preclinical work to clinical studies. • Contact us to discuss your project: http://ow.ly/ssRR50AySCB
Our deep understanding of viral vectors incorporates repeated successes in viral manufacturing across a breadth of platforms including: adenovirus, AAV, influenza, HSV, poxviruses (i.e., MVA and vaccinia), retroviruses (i.e., HIV and lentivirus), maraba virus and oncolytic viruses, VSV, VLPs, lytic and non-lytic viruses, enveloped and non-enveloped viruses and more.
Our Lyon facility provides a wider immunology offering than traditional CROs, also providing immune-monitoring through biomarker capabilities. • Learn more here: http://ow.ly/Ipua50Axge1
ABL has technical agility. • We can transfer your method to our laboratories, or our team of scientists can work with you to adapt or develop a novel method. • Learn more: https://ablinc.com/
ABL manages the intricacies of supply chain logistics worldwide. • We helped a customer who was performing vaccine research in Africa to successfully clear multiple tiers of customs and meet the vaccine's refrigeration needs from the point of manufacturing to administration. • Contact us to see what we can do for you: http://ow.ly/4zxW50AxeVs
Over here, GMP viral vector manufacturing production is adaptable and nimble to assure products for our clients' clinical trials meet their requirements. • Our highly specialized experts do this by focusing on creating solutions that enable speed to market utilizing their cross-functional viral vector knowledge. • Learn more: https://lnkd.in/dPFD3j7
Our wide breadth of viral vector knowledge enables us to accelerate the timelines of optimizing the development for specific vectors. • We apply past learnings to modify existing processes, or create new processes, to minimize development time. • We collaborate globally to expedite our client?s cell and gene therapies, oncolytic's and vaccines by optimizing processes for suspension culture and fixed bed bioreactors to manufacture virus vectors. • Learn more: https://lnkd.in/eWxjRVE
!!! Hiring: ABL is looking for a Program Manager. • This position manages biomanufacturing process development and cGMP manufacturing projects of viral and mammalian products for clinical application as vaccines and biologics, including gene therapy applications. • BS/MS in a scientific related field required, PMP Certification preferred. • Apply here: http://ow.ly/P0TO50AwSZk
iCELLis 500 adds to ABL's broad portfolio of adherent cell growth options. • iCELLis 500 significantly increases volumetric productivity verses classical adherent methods (i.e. roller bottles, cell factory systems, HYPERStacks, etc.); meeting capacity requirements, providing predictable streamlined scalability and accelerating time to market. • Learn more: http://ow.ly/9RcG50As2DZ • 📸: Pall Corporation
